A Novel Approach in Cancer Immunotherapy: CART-CELL Therapy

Chimeric Antigen Receptor (CAR) T-cell therapy is a progressive invention in cancer immunotherapy. In recent years, the emergence of CAR T therapies in clinical practice has led to a new advancement in the treatment of patients diagnosed with solid tumours and haematological malignancies. The most serious negative impacts of CAR T-cell therapy include cytokine release syndrome, which may affect antitumor efficacy. This is said to be an innovation in immunotherapy, targeted against tumour-associated antigens. Among the numerous methods to treat cancer, one method is CAR T-cell therapy, which treats cancer in association with the immune system. In this review, epidemiology and aetiology of cancer were discussed briefly, along with properties of cancer cells, cancer immunotherapy and chimeric antigen receptor design. Major Findings: CAR T-cell therapy has emerged as a promising and innovative strategy in cancer immunotherapy, utilizing genetically engineered T-cells to specifically recognize and eliminate tumor-associated antigens. In the present review, targeted therapies, particularly those directed against CD19, have demonstrated significant clinical success in hematological malignancies such as leukemia and lymphoma. However, challenges such as cytokine release syndrome, neurological toxicities, and limited effectiveness in solid tumors continue to restrict its widespread clinical application. Targets and current challenges of CAR T-cell therapy were discussed in this review.

View article page

Download PDF